Retatrutide
Final price and live stock are confirmed on the partner page before checkout.
Entry concentration for initial titration and pilot metabolic-pathway protocols.
Retatrutide (LY3437943) research compound - a next-generation triple agonist targeting the GLP-1, GIP, and glucagon (GCG) receptors. Studied in metabolic, obesity, and incretin-pathway research as the successor to single- and dual-agonist peptides such as Semaglutide and Tirzepatide. For laboratory research purposes only.
Real Certificate of Analysis from Baltic Peptides · View all COAs
In stock now at our partner Baltic Peptides - GLP-1/GIP/glucagon triple agonist.
Order Retatrutide at Baltic PeptidesSKU: BBL-209-5mg
Checkout: Current partner listing and availability
Product Overview
Retatrutide (LY3437943) research compound - a next-generation triple agonist targeting the GLP-1, GIP, and glucagon (GCG) receptors. Studied in metabolic, obesity, and incretin-pathway research as the successor to single- and dual-agonist peptides such as Semaglutide and Tirzepatide. For laboratory research purposes only.
Batches are tested by independent EU laboratories using HPLC for purity, with identity confirmed against a reference standard. Certificates of analysis carry the batch number and testing date, and the ones we hold are published on our lab reports page. Ask the partner for the batch-specific certificate at checkout.
Alternative Research Intensities
*Independent research variants for specific volumetric study parameters.
Related Research Peptides
Tirzepatide
AOD9604
